<DOC>
	<DOCNO>NCT02683291</DOCNO>
	<brief_summary>There consensus best immunosuppressive regimen elderly people . The aim study evaluate efficacy sirolimus associate tacrolimus elderly kidney transplant recipient . The investigator conduct single-center prospective randomize study compare combination tacrolimus sirolimus reduce dose rate ( tacrolimus + sirolimus group ) tacrolimus mycophenolate ( tacrolimus + mycophenolate group ) . The investigator include kidney transplant patient 60 year age . The investigator evaluate estimate glomerular filtration rate incidence cytomegalovirus 12 month follow-up .</brief_summary>
	<brief_title>Sirolimus Associated With Tacrolimus Low Doses Elderly Kidney Transplant Patients</brief_title>
	<detailed_description>Study Design This single-center , prospective , 12-month randomize controlled trial aim compare sirolimus associate tacrolimus elderly renal transplant patient safety incidence cytomegalovirus ( CMV ) infection . Treatments In control group ( Tacrolimus + Mycophenolate ) investigator use tacrolimus ( start 0.1 mg/kg twice daily adjust target serum level 4-8ng/ml third month 3-7ng/ml third month 12th month ) mycophenolate sodium 720 mg twice daily . A dose reduction mycophenolate sodium 720 mg/day accept due possible side effect drug . In treatment group ( Tacrolimus + sirolimus ) investigator use tacrolimus ( start 0.1 mg/kg twice daily adjust target serum level 4-8 ng/ml third month 3-7 ng/ml third month 12th month ) sirolimus 2 mg/day ( adjust serum level 4-8 ng/ml throughout study period ) . In group , patient receive prednisone 30 mg/day ( first month weekly reduction 5 mg/day end second month ) . Induction therapy consist basiliximab antithymocyte globulin ( Thymoglobulin , GenzymeÂ® ) . Thymoglobulin use patient panel reactivity class I great 50 % ( dose 1mg/kg 5 day ) .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients age 60 year recipient compatible renal transplant 1 . Receptors multiple organ ; 2. nonheart beat donor ; 3. donor age 5 65 year ; 4 . Patients body mass index great 35</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>sirolimus</keyword>
	<keyword>cytomegalovirus</keyword>
	<keyword>age</keyword>
</DOC>